- Adjusted EBITDA increased 10% year-over-year to $100 million, and adjusted EPS rose to $2.10 from $1.56 last year.
- Debt was reduced by $250 million year-to-date, with $200 million of JV proceeds used to pay down Term Loan A.
- Free cash flow was a net outflow of $8 million in Q2, impacted by working capital timing, tax payments, and tariffs.
- Gross margin expanded by 3 percentage points year-over-year to 40%, driven mainly by the JV deconsolidation and integration synergies.
- ICU Medical reported Q2 2025 revenue of $544 million, with 2% organic growth and a 6% decline reported due to the IV Solutions joint venture deconsolidation.
Related items and other data are not available for this feed item.
Dafinchi